Femasys Inc (FEMY)vsResMed Inc (RMD)
FEMY
Femasys Inc
$0.37
-1.75%
HEALTHCARE · Cap: $925,180
RMD
ResMed Inc
$196.04
+0.89%
HEALTHCARE · Cap: $28.25B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 241377% more annual revenue ($5.54B vs $2.29M). RMD leads profitability with a 27.4% profit margin vs 0.0%. RMD earns a higher WallStSmart Score of 73/100 (B).
FEMY
Hold38
out of 100
Grade: F
RMD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FEMY.
Margin of Safety
-26.9%
Fair Value
$204.63
Current Price
$196.04
$8.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.9% year-over-year
Strong operational efficiency at 35.3%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : FEMY
The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 39.9% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.
Bear Case : FEMY
The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
FEMY profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.
RMD carries more volatility with a beta of 0.78 — expect wider price swings.
FEMY is growing revenue faster at 39.9% — sustainability is the question.
RMD generates stronger free cash flow (520M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (73/100 vs 38/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Femasys Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Femasys Inc. is an innovative medical technology company dedicated to transforming women's healthcare through its proprietary solutions for diagnosing and treating gynecological conditions. With a focus on non-surgical alternatives, Femasys is addressing prevalent issues such as uterine fibroids and contraception, positioning itself as a key player in the growing field of women’s health. As demand for minimally invasive treatments continues to rise, the company is strategically equipped to enhance patient outcomes and efficiency in healthcare delivery. By concentrating on significant unmet needs, Femasys aims to set new standards for care in this essential sector.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?